Alkermes Reports Promising Findings from Vibrance-2 Study of Alixorexton for Narcolepsy Type 2 Alkermes has announced successful phase 2 study results for Alixorexton, marking a potential breakthrough treatment for Narcolepsy Type 2, paving the way for phase 3 trials.

Alkermes Reports Promising Findings from Vibrance-2 Study of Alixorexton for Narcolepsy Type 2 #USA #Dublin #Alkermes #Narcolepsy #Alixorexton

Alkermes Unveils Promising Findings on Alixorexton at World Sleep 2025 Alkermes is set to present significant insights from the Vibrance-1 Phase 2 study on alixorexton for narcolepsy Type 1 at World Sleep 2025, along with an investor webcast discussion.

Alkermes Unveils Promising Findings on Alixorexton at World Sleep 2025 #Ireland #Dublin #Alkermes #Alixorexton #Vibrance-1

Alkermes Unveils Encouraging Results from Vibrance-1 Study of Alixorexton for Narcolepsy Type 1 Patients Alkermes announces significant findings from the Vibrance-1 study, showcasing the beneficial effects of Alixorexton in improving wakefulness and cognitive functions in Narcolepsy Type 1 patients.

Alkermes Unveils Encouraging Results from Vibrance-1 Study of Alixorexton for Narcolepsy Type 1 Patients #USA #Dublin #Alkermes #Narcolepsy #Alixorexton

Alkermes Unveils Encouraging Phase 2 Results for Alixorexton as Treatment for Narcolepsy Type 1 Alkermes announces promising outcomes from its Vibrance-1 Phase 2 study on Alixorexton, indicating significant improvements in wakefulness for narcolepsy type 1 patients.

Alkermes Unveils Encouraging Phase 2 Results for Alixorexton as Treatment for Narcolepsy Type 1 #USA #Dublin #Alkermes #Narcolepsy #Alixorexton